A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY. (June 2017) - Le Gouill, S.